Drug Trial Radar · NCT05255302
De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction
Last checked: Nov 20, 2026Latest source record: Apr 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,360
Planned (sponsor's estimate)
Start
May 2, 2022
Primary completion
May 2025
Study completion Jun 1, 2029
Sponsor
- Lead sponsor
- Intergroupe Francophone de Cancerologie ThoraciqueAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Immunotherapeutic approaches recently have demonstrated clinical efficacy in several cancer types, including melanoma and NSCLC. As a matter of fact, first registration trials of immune-checkpoints inhibitors (ICI) in second-line settings (pembrolizumab as well as nivolumab or atezolizumab) had stated that ICI could be continued until disease progression or not tolerable toxicity, up to 5 years. This is only for the first-line registration studies that the arbitrary maximal duration of treatment of 2 years was set up by the Companies sponsoring such trials. The aim is to study a de-escalation scheme of treatment from 2 years of immunotherapy to 6 months (27-weeks), in patients with controlled disease.
Conditions
- Metastatic NSCLC
Interventions
Pembrolizumab before randomizationDrug
Pembrolizumab 200 mg every 3 weeks before randomization
ChemotherapyDrug
Platinum doublet - 4 cycles: either paclitaxel-carboplatin for patient with SCC or pemetrexed-platinum salt followed by 2 cycles of pemetrexed until reaching the 6 months time-point for randomization Carboplatin AUC 5 for non-squamous cell carcinoma and AUC6 for squamous cell carcinoma every 3 weeks or cisplatin 75 mg/m² every 3 weeks Pemetrexed 500 mg/m² every 3 weeks or paclitaxel 175 mg/m² every 3 weeks
PemetrexedDrug
Maintenance pemetrexed after randomization Pemetrexed 500 mg/m² every 3 weeks
Pembrolizumab after randomizationDrug
Pembrolizumab 200 mg every 3 weeks after randomization
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase II: 18-month overall survival (OS)Time frame: 18 months after inclusion
- Phase III: overall survivalTime frame: about 24 months after randomization
Locations
44 sites in 1 country. Site status is shown where the registry gives one.
Aix-en-Provence - CH
Aix-en-Provence, France · Not yet recruiting
Amiens - Clinique de l'Europe
Amiens, France · Not yet recruiting
Angers - CHU
Angers, France · Not yet recruiting
Avignon - CH
Avignon, France · Not yet recruiting
Besançon - CHU
Besançon, France · Not yet recruiting
Bordeaux - Polyclinique
Bordeaux, France · Not yet recruiting
CHU de Bordeaux
Bordeaux, France · Not yet recruiting
Caen - CHU Côte de Nacre
Caen, France · Recruiting
Cannes - CH
Cannes, France · Not yet recruiting
Chauny - Centre Hospitalier
Chauny, France · Not yet recruiting
CH
Colmar, France · Not yet recruiting
Centre Georges François Leclerc
Dijon, France · Not yet recruiting
CHRU Grenoble
Grenoble, France · Active not recruiting
La Roche Sur Yon - CH
La Roche-sur-Yon, France · Not yet recruiting
CH de Versailles
Le Chesnay, France · Not yet recruiting
Centre Hospitalier - Pneumologie
Le Mans, France · Not yet recruiting
CHRU de Lille
Lille, France · Not yet recruiting
CHU de Limoges
Limoges, France · Not yet recruiting
Lyon - Hôpital Jean Mermoz
Lyon, France · Not yet recruiting
Marseille - Hôpital Européen
Marseille, France · Not yet recruiting
Meaux - CH
Meaux, France · Not yet recruiting
Metz - Hôpital Robert Schuman
Metz, France · Active not recruiting
Hôpital Arnaud de Villeneuve
Montpellier, France · Not yet recruiting
Centre Hospitalier
Mulhouse, France · Not yet recruiting
Nantes - CHU Hôpital Laënnec
Nantes, France · Not yet recruiting
Nice - CRLCC
Nice, France · Not yet recruiting
Orléans - CHR
Orléans, France · Not yet recruiting
Paris - APHP - Hopital Tenon
Paris, France · Active not recruiting
Institut CURIE
Paris, France · Not yet recruiting
Hôpital Bichat - Claude - Bernard
Paris, France · Recruiting
Reims - CHU
Reims, France · Not yet recruiting
Rouen - CHU
Rouen, France · Not yet recruiting
Centre René Huguenin
Saint-Cloud, France · Not yet recruiting
CHU Saint-Etienne Pneumologie
Saint-Etienne, France · Not yet recruiting
Hôpital privé de la Loire
Saint-Etienne, France · Not yet recruiting
Institut de Cancérologie de l'Ouest - René Gauducheau
Saint-Herblain, France · Not yet recruiting
Saint-Nazaire - Clinique Mutualiste de l'Estuaire
Saint-Nazaire, France · Not yet recruiting
CHU de La Réunion-Site Sud
Saint-Pierre, France · Not yet recruiting
Centre Hospitalier
Saint-Quentin, France · Not yet recruiting
Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg
Strasbourg, France · Not yet recruiting
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.